JAK-STAT Targeting Offers Novel Therapeutic Opportunities in Sepsis.
Janus kinase
immunosuppression
multiple organ failure
sepsis
signal transducer and activator of transcription
Journal
Trends in molecular medicine
ISSN: 1471-499X
Titre abrégé: Trends Mol Med
Pays: England
ID NLM: 100966035
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
31
03
2020
revised:
21
05
2020
accepted:
10
06
2020
pubmed:
8
7
2020
medline:
16
10
2021
entrez:
8
7
2020
Statut:
ppublish
Résumé
Sepsis is a life-threatening condition caused by exaggerated host responses to infections taking place in two phases: (i) a systemic (hyper)inflammatory response syndrome (SIRS), participating in multiple organ failure (MOF), a major complication of septic shock, followed by (ii) a compensatory anti-inflammatory response syndrome (CARS), leading to sepsis-induced immunosuppression and resulting in late infections and long-term mortality. The Janus kinase-signal transducer and activator of transcription (JAK-STAT)-dependent signaling pathway is involved in both manifestations, hence playing a key role during sepsis. It is also involved in emergency myelopoiesis, which participates in host defense. The aim of this review is to highlight and refine the recent implications of this signaling pathway in sepsis and illustrate why its central position makes it a potential biomarker and therapeutic target.
Identifiants
pubmed: 32631717
pii: S1471-4914(20)30158-1
doi: 10.1016/j.molmed.2020.06.007
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Biomarkers
0
STAT Transcription Factors
0
Janus Kinases
EC 2.7.10.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
987-1002Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.